Autres langues Shanghai Junshi Biosciences Co., Ltd.

Actions

1877

CNE100003FF7

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:06 30/04/2024			Varia. 5j.	Varia. 1 janv.
11,76 ^HKD	+8,49%		+26,59%	-39,51%

29/04	Shanghai Junshi Biosciences Co. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
25/04	Shanghai Junshi Biosciences reçoit l'approbation de Hong Kong pour le toripalimab, un médicament contre le cancer	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab	25/04
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab	25/04
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region	24/04
Shanghai Junshi Biosciences Co., Ltd. Announces Executive Changes	24/04
Junshi Biosciences Gets Nod to Register Toripalimab Injection	08/04
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04
Shanghai Junshi Biosciences Supplemental NDA for Lipid Drug Accepted by NMPA	03/04
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection	02/04
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.	02/04
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates	29/03
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates	29/03
Junshi Bio's 2023 Loss Widens, Misses Estimates	26/02
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Junshi Biosciences Proposes Share Buyback	02/02
Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority	02/02
Junshi Says NDA for Anti-Cancer Drug Accepted By Singapore's HSA	01/02
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptation of New Drug Application of Toripalimab by Singapore Health Sciences Authority	01/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Shanghai Junshi Biosciences Co., Ltd.

Actions

1877

CNE100003FF7

Autres langues

Filtres